Form 8-K - Current report:
SEC Accession No. 0001193125-20-318091
Filing Date
2020-12-15
Accepted
2020-12-15 16:00:54
Documents
13
Period of Report
2020-12-14
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d88073d8k.htm   iXBRL 8-K 26756
2 EX-3.1 d88073dex31.htm EX-3.1 94875
  Complete submission text file 0001193125-20-318091.txt   269457

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sgmo-20201214.xsd EX-101.SCH 3067
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sgmo-20201214_lab.xml EX-101.LAB 18125
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sgmo-20201214_pre.xml EX-101.PRE 11403
6 EXTRACTED XBRL INSTANCE DOCUMENT d88073d8k_htm.xml XML 3489
Mailing Address 7000 MARINA BLVD BRISBANE CA 94005
Business Address 7000 MARINA BLVD BRISBANE CA 94005 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 201389572
SIC: 2836 Biological Products, (No Diagnostic Substances)